Yifan Pharmaceutical's Unit Gets Nod to Market Famotidine Injection

MT NewswiresSep 19 00:45 ET

Yifan Pharmaceutical (002019.SZ): Wholly-owned subsidiary Famosi Injection receives pharmaceutical registration certificate.

Yifan Pharmaceutical (002019.SZ) announced on September 18 that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., has recently received the "Drug Registration Certificate" for Famotidine Injection issued by the National Medical Products Administration. Famotidine Injection is mainly used for upper gastrointestinal bleeding caused by peptic ulcers, as well as gastric and duodenal mucosal erosion bleeding caused by various reasons other than tumors and esophageal and gastric fundus varices.

Gelonghui FinanceSep 18 06:19 ET

Further Weakness as Yifan Pharmaceutical (SZSE:002019) Drops 3.2% This Week, Taking Three-year Losses to 40%

Simply Wall StSep 14 20:57 ET

Yifan Pharmaceutical (002019.SZ) interim equity distribution: 1 yuan per 10 shares.

yifan pharmaceutical (002019.SZ) announced that the company's 2024 interim equity distribution scheme is: to distribute equity to shareholders for half a year...

Zhitong FinanceSep 13 05:38 ET

Yifan Pharmaceutical (002019.SZ): The company has not produced products for this indication (monkeypox).

Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform on August 31st that the company does not produce products for this indication (monkeypox); at the same time, kindly remind investors not to believe rumors, to rationally distinguish various types of information, and to pay attention to investment risks.

Gelonghui FinanceSep 2 03:39 ET

Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Might Not Be As Mispriced As It Looks

Simply Wall StAug 19 03:32 ET